PRISM BioLab (206A) · TargetRestated
Demonstrating the Utility of PepMetics Technology and Establishing an Industry-Leading Position
First written in FY2024. 4 of 5 entries say "Restated". Latest entry: 2026-05-18.
5entries
3years
2from disclosures
How it moved
Same theme, other companies
Demonstrating the Utility of PepMetics Technology and Establishing an Industry-Leading PositionA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2025RestatedAnnual report
「A key management priority is to prove the utility of this technology, lead the industry in its application, and maintain our competitiveness.」
Proving the utility of PepMetics technology, industry leadership, and maintaining competitiveness continue to be treated as key priorities. - FY2025-H1RestatedAnnual report
「We have developed this proprietary drug discovery platform into PepMetics® technology and established a technology for identifying promising compounds against targets that have historically been considered difficult for drug discovery.」
The company has reiterated that it has established a technology platform for applying PepMetics technology to challenging drug targets. - FY2024First statedAnnual report
「A key management priority is to prove the utility of this technology, lead the industry in its application, and maintain our competitiveness.」
The company has positioned validation of its proprietary technology, maintenance of competitiveness, and industry leadership as management priorities.